• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

    2/8/23 5:24:52 PM ET
    $AVNS
    Industrial Specialties
    Health Care
    Get the next $AVNS alert in real time by email
    SC 13G/A 1 paradice-avns123122a2.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*



    Avanos Medical, Inc.

    (Name of Issuer)

     

    Common Stock - $0.01 Par Value

    (Title of Class of Securities)

     

    05350V106

    (CUSIP Number)

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  05350V106
     SCHEDULE 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Paradice Investment Management LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    1,071,849
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,343,232
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,343,232
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.0%
    12
    TYPE OF REPORTING PERSON
     
    IA

     

     


     

    CUSIP No.  05350V106
     SCHEDULE 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Paradice Investment Management Pty Ltd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Australia
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    1,071,849
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,343,232
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,343,232
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.0%
    12
    TYPE OF REPORTING PERSON
     
    HC

     

     
     

     

    CUSIP No.  05350V106
     SCHEDULE 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Avanos Medical, Inc.

    (b) Address of Issuer’s Principal Executive Offices

    5405 Windward Parkway, Suite 100 South

    Alpharetta, Georgia 30004

    Item 2.(a) Name of Person Filing

    Paradice Investment Management LLC

    Paradice Investment Management Pty Ltd

    (b) Address of Principal Business Office, or, if none, Residence

    Paradice Investment Management LLC

    250 Fillmore St, Suite 425

    Denver, Colorado 80206

    Paradice Investment Management Pty Ltd

    Level 27

    The Chifley Tower

    2 Chifley Square

    Sydney NSW 2000

    Australia

    (c) Citizenship

    Paradice Investment Management LLC - Delaware

    Paradice Investment Management Pty Ltd - Australia

     (d) Title of Class of Securities

    Common Stock - $0.01 Par Value (the “Common Stock”)

     (e) CUSIP No.:

    05350V106

     
     

     

    CUSIP No.  05350V106
     SCHEDULE 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

     
     

     

    CUSIP No. 05350V106
     SCHEDULE 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    The information as of the filing date required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not Applicable.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No.  05350V106
     SCHEDULE 13G/A
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 8, 2023

     

     

      Paradice Investment Management LLC
           
      By:   Lucinda Hill
        Name:  Lucinda Hill
        Title:  Chief Compliance Officer

     

      Paradice Investment Management Pty Ltd
           
      By:   Peter Manley
        Name:  Peter Manley
        Title:  Chief Operating Officer

     

     
    CUSIP No. 05350V106
     SCHEDULE 13G/A
    Page 8 of 8 Pages

     

     JOINT FILING AGREEMENT

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned hereby agree that the Statement on this Schedule 13G/A, dated February 10, 2022, (the "Schedule 13G/A"), with respect to the Common Stock of Avanos Medical, Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to the Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

     

    IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 8th day of February 2023.

     

     

      Paradice Investment Management LLC
           
      By:   Lucinda Hill
        Name:  Lucinda Hill
        Title:  Chief Compliance Officer

     

      Paradice Investment Management Pty Ltd
           
      By:   Peter Manley
        Name:  Peter Manley
        Title:  Chief Operating Officer

     

    Get the next $AVNS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVNS

    DatePrice TargetRatingAnalyst
    7/25/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    5/22/2023$31.00Buy
    CL King
    2/24/2022$47.00 → $41.00Overweight
    Keybanc
    1/7/2022$37.00 → $36.00Underweight
    Morgan Stanley
    8/4/2021$45.00 → $41.00Underweight
    Morgan Stanley
    8/4/2021$60.00 → $45.00Overweight → Equal-Weight
    Stephens
    8/4/2021$55.00 → $47.00Overweight
    Keybanc
    More analyst ratings

    $AVNS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Shimer Julie Ann bought $9,925 worth of shares (500 units at $19.85), increasing direct ownership by 1% to 50,090 units (SEC Form 4)

      4 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      3/11/24 5:15:37 PM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avanos Medical, Inc. Announces First Quarter 2025 Results

      ALPHARETTA, Ga., May 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported first quarter 2025 financial results. "In my first couple of weeks at Avanos, I've noticed that the transformation efforts made around the portfolio, the organizational structure and cost management have positioned us well to accelerate our growth profile," said David Pacitti, Avanos's recently appointed Chief Executive Officer. Pacitti continued, "I really like the energy and strategic focus we have right now, which can be leveraged for more consistent execution, to identify more go-t

      5/6/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2025 Financial Results

      ALPHARETTA, Ga., April 28, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2025 on Tuesday, May 6 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Dave Pacitti, chief executive officer, Jason Pickett, interim chief financial officer, Scott Galovan, senior vice president, strategy and corporate development, and Gary Blackford, Avanos board chairman. To instantly jo

      4/28/25 7:47:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Expands Direct Operations for MIC-KEY* Enteral Feeding Products in the UK starting July 2025

      ZAVENTEM, Belgium, April 2, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) a global medical technology company, today announced that it will take direct responsibility for the sales and distribution of its MIC-KEY enteral feeding products in the United Kingdom, effective 25 July 2025. This strategic move reflects Avanos' commitment to prioritizing customer needs, enhancing product availability into the future, and providing a seamless experience for healthcare providers and patients. For the past 29 years, Vygon UK, a leading supplier of surgical and medical devices has

      4/2/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Avanos Medical downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Avanos Medical from Overweight to Sector Weight

      7/25/23 6:15:12 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • CL King initiated coverage on Avanos Medical with a new price target

      CL King initiated coverage of Avanos Medical with a rating of Buy and set a new price target of $31.00

      5/22/23 8:52:10 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Keybanc reiterated coverage on Avanos Medical with a new price target

      Keybanc reiterated coverage of Avanos Medical with a rating of Overweight and set a new price target of $41.00 from $47.00 previously

      2/24/22 4:48:01 AM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avanos Medical Inc.

      SC 13G - AVANOS MEDICAL, INC. (0001606498) (Subject)

      11/14/24 1:28:34 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

      SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)

      2/14/24 11:41:02 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

      SC 13G/A - AVANOS MEDICAL, INC. (0001606498) (Subject)

      2/13/24 4:58:57 PM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Pickett Jason Marc claimed ownership of 40,113 shares (SEC Form 3)

      3 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      4/29/25 3:45:04 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Amendment: New insider Pacitti David claimed ownership of 242,047 shares (SEC Form 3)

      3/A - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      4/24/25 5:00:37 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • New insider Pacitti David claimed ownership of 242,047 shares (SEC Form 3)

      3 - AVANOS MEDICAL, INC. (0001606498) (Issuer)

      4/24/25 12:08:46 PM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Leadership Updates

    Live Leadership Updates

    See more
    • Avanos Medical Announces Appointment of David Pacitti as Chief Executive Officer

      ALPHARETTA, Ga., March 17, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. Pacitti joins Avanos with a distinguished career in the healthcare sector, most recently serving as president of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. In this capacity, he played a pivotal role in driving strategic growth and operational excellence while leading the marketing, sales, service, and support

      3/17/25 7:30:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. Appoints Indrani Franchini to Board of Directors

      ALPHARETTA, Ga., July 1, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Indrani Franchini has been appointed as a new independent member of the Avanos board of directors. "We are excited to welcome Indrani Franchini to the Avanos board," remarked Gary Blackford, Avanos board chair. "Her experience with a broad range of global companies will be invaluable to Avanos as we pursue our vision of getting patients back to the things that matter." "Avanos is committed to addressing some of today's most important healthcare needs and I am thrilled to join it

      7/1/24 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. Appoints Sig Delgado as Senior Vice President, Integrated Supply Chain

      ALPHARETTA, Ga., May 13, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today announced that Sigfrido (Sig) Delgado has been appointed senior vice president, integrated supply chain. In this role, Delgado will lead the teams focused on implementing continuous improvements within the Company's end-to-end supply chain capabilities worldwide. Delgado joins Avanos from Jabil Healthcare, the industry's largest global provider of healthcare manufacturing solutions, where he most recently served as vice president of its global medical technology business. His background includ

      5/13/24 7:15:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Avanos Medical Inc.

      10-Q - AVANOS MEDICAL, INC. (0001606498) (Filer)

      5/6/25 4:17:36 PM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)

      5/6/25 7:07:11 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - AVANOS MEDICAL, INC. (0001606498) (Filer)

      4/30/25 9:47:43 AM ET
      $AVNS
      Industrial Specialties
      Health Care

    $AVNS
    Financials

    Live finance-specific insights

    See more
    • Avanos Medical, Inc. Announces First Quarter 2025 Results

      ALPHARETTA, Ga., May 6, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported first quarter 2025 financial results. "In my first couple of weeks at Avanos, I've noticed that the transformation efforts made around the portfolio, the organizational structure and cost management have positioned us well to accelerate our growth profile," said David Pacitti, Avanos's recently appointed Chief Executive Officer. Pacitti continued, "I really like the energy and strategic focus we have right now, which can be leveraged for more consistent execution, to identify more go-t

      5/6/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. to Webcast Conference Call Discussing First Quarter 2025 Financial Results

      ALPHARETTA, Ga., April 28, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) will webcast its conference call discussing financial results and business highlights for the first quarter 2025 on Tuesday, May 6 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day. The conference call will be hosted by Dave Pacitti, chief executive officer, Jason Pickett, interim chief financial officer, Scott Galovan, senior vice president, strategy and corporate development, and Gary Blackford, Avanos board chairman. To instantly jo

      4/28/25 7:47:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care
    • Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2024 Results

      ALPHARETTA, Ga., Feb. 26, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE:AVNS) today reported fourth quarter and full-year 2024 results. "We are pleased with our fourth quarter results, which delivered 5% organic growth and continued execution on each of our transformation initiative priorities," said Michael Greiner, Avanos's interim chief executive officer. Greiner continued, "For the full year, we generated $83 million of free cash flow and $108 million of adjusted EBITDA. We currently have net debt of approximately $20 million. We believe our strong financial position wil

      2/26/25 7:00:00 AM ET
      $AVNS
      Industrial Specialties
      Health Care